pdf   xlsx method abbreviations

lung cancer : non small cell (NSCLC), ... versus non active control, meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.89 [0.69, 1.14]< 179%3 studies (3/-)81.6 %some concernnot evaluable moderatecrucial-
progression or deaths (PFS) 0.70 [0.54, 0.92]< 179%2 studies (2/-)99.5 %lownot evaluable highimportant-
events or deaths (EFS) 0.90 [0.74, 1.10]< 10%1 study (1/-)85.0 %NAnot evaluable non important-
objective responses (ORR) 4.09 [0.84, 19.91]> 172%2 studies (2/-)95.9 %lownot evaluable highnon important-

safety endpoints 00

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.